Valuation : Regent Pacific Group Limited

Market Cap	30.89M 242M 26.58M 25.03M 22.8M 42.66M 2.94B 42.83M 297M 115M 1.5B 116M 113M 4.74B	P/E 2024	-2.39x	P/E 2025	-7.63x
Enterprise Value	34.67M 272M 29.83M 28.09M 25.59M 47.89M 3.3B 48.08M 333M 129M 1.68B 130M 127M 5.32B	EV / Sales 2024	19.4x	EV / Sales 2025	121x
Free-Float	31.54%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Regent Pacific Group Limited

Hong Kong S.E.HKD

Markets		Quality
Hong Kong S.E.	575	Delayed
Deutsche Boerse AG	RPG	Delayed
Börse Stuttgart	RPG	Delayed

Dynamic Chart

Latest news : Regent Pacific Group Limited

09-01	Regent Pacific Gets $4.5 Million Milestone Payment from Fosun Pharma Unit	MT
09-01	Regent Pacific Group Ltd. Provides Update on Receipt of Payment from Fosun Wanbang Pharmaceutical Group Co., Ltd. and Update on Senstend Commercialisation in the PRC	CI
08-25	Regent Pacific Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-03	Regent Pacific Group Limited Provides Group Earnings Guidance for the Period Ended June 30, 2026	CI
06-17	Regent Pacific's Senstend Approved in China	MT
06-16	Regent Pacific Group Limited Receives NMPA Approval For Senstend And Announces Commercialisation in China	CI
05-04	Regent Pacific Proposes RSU Scheme to Incentivize Employees	MT
04-28	Regent Pacific Group Limited Auditor Raises 'Going Concern' Doubt	CI
03-26	Regent Pacific Group Limited Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-10	Regent Pacific Unit Deep Longevity Taps Senior Executives Ahead of U.S. Launch; Shares Jump 6%	MT
12-01	Regent Pacific's Unit to Launch U.S. Operations in Early 2026; Shares Jump 6%	MT
12-01	Regent Pacific says Deep Longevity to launch U.S. expansion in Q1 2026	RE
25-08-27	Regent Pacific Group Limited Reports Earnings Results for the Half Year Ended June 30, 2025	CI

More news

Managers and Directors : Regent Pacific Group Limited

Manager	Title	Age	Since
Jamie Gibson CEO	Chief Executive Officer	60	2002-04-30
Yui Fui Wong DFI	Director of Finance/CFO	51	2010-12-31
Michael Wyllie CTO	Chief Tech/Sci/R&D Officer	75	-

Director	Title	Age	Since
Jamie Gibson BRD	Director/Board Member	60	2001-12-31
Jayne Allison Sutcliffe BRD	Director/Board Member	62	2000-05-31
Jim Mellon CHM	Chairman	70	1993-12-31

More insiders

Regent Pacific Group Ltd, formerly Endurance RP Ltd is an investment holding company principally engaged in biopharma and investment businesses. The Company operates its business through two segments. The Biopharma segment is engaged in the research, development, manufacture, marketing and sale of pharmaceutical products. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The Company is also engaged in aging research and developing artificial intelligence (AI) models and tool products related to aging research. It offers aging and longevity clocks to the longevity clinics, preventative medicine organizations, health clubs, insurance companies, and aging research institutions.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-09-09	HK$0.8300	+1.84%	10,500
26-09-08	HK$0.8150	-1.21%	272,275
26-09-07	HK$0.8250	-2.94%	12,386
26-09-04	HK$0.8500	0.00%	0
26-09-03	HK$0.8500	0.00%	20,000

Delayed Quote Hong Kong S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Hong Kong S.E. 04:08:06 2026-09-09 EDT			5-day change	1st Jan Change
0.8300 ^HKD	+1.84%		-1.78%	-22.43%

1 day	+1.84%
1 week	-1.78%
Current month	-1.78%
1 month	-8.79%
3 months	+36.07%
6 months	-7.78%
Current year	-22.43%

1 week	0.78	0.85
1 month	0.78	0.97
Current year	0.57	1.22
1 year	0.57	1.22
3 years	0.32	1.24
5 years	0.25	3.86
10 years	0.25	15.8

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/5/23	Julie Oates	Other	Director	3,639,574	0.1517%
6/5/23	Jim Mellon	Other	Founder	2,455,657,694	-
6/5/23	Jamie Gibson	Other	Chief Executive Officer	149,249,568	6.2202%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENT PACIFIC GROUP LIMITED	+1.84%	-1.78%	+10.67%	-17.00%	30.33M
ELI LILLY AND COMPANY	+0.11%	-2.94%	+50.01%	+89.07%	1,002B
JOHNSON & JOHNSON	-0.35%	-2.45%	+51.71%	+65.05%	649B
ABBVIE INC.	+0.69%	-4.53%	+18.74%	+67.65%	440B
ROCHE HOLDING AG	-0.80%	-0.43%	+28.92%	+36.94%	346B
NOVARTIS AG	-0.13%	-14.97%	+9.41%	+26.44%	263B
ASTRAZENECA PLC	-1.90%	-2.72%	-2.72%	+10.93%	250B
AMGEN INC.	-0.24%	-11.58%	+39.86%	+49.61%	213B
NOVO NORDISK A/S	-1.06%	-4.23%	-14.70%	-57.76%	201B
GILEAD SCIENCES, INC.	-0.54%	-2.59%	+25.89%	+89.17%	182B
Average	-0.22%	-2.21%	+21.78%	+36.01%	354.37B
Weighted average by Cap.	-0.25%	-2.39%	+32.14%	+56.09%

Regent Pacific Group Limited Stock

Stocks

575

KYG3042R1314

Pharmaceuticals

Valuation : Regent Pacific Group Limited

Chart: Regent Pacific Group Limited

Latest news : Regent Pacific Group Limited

Quotes and Performance

Price Extremes

Managers and Directors : Regent Pacific Group Limited

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

	2024	2025
Net sales	719K 5.64M 619K 583K 531K 993K 68.42M 997K 6.9M 2.67M 34.86M 2.7M 2.64M 110M	363K 2.85M 312K 294K 268K 501K 34.54M 503K 3.49M 1.35M 17.6M 1.36M 1.33M 55.75M
Net income	-4.48M -35.15M -3.86M -3.63M -3.31M -6.19M -426M -6.22M -43.04M -16.63M -217M -16.83M -16.46M -688M	-4.71M -36.94M -4.05M -3.82M -3.48M -6.51M -448M -6.53M -45.23M -17.48M -228M -17.69M -17.3M -723M
Net Debt	3.22M 25.23M 2.77M 2.61M 2.37M 4.44M 306M 4.46M 30.89M 11.94M 156M 12.08M 11.82M 494M	3.78M 29.67M 3.26M 3.07M 2.79M 5.23M 360M 5.25M 36.33M 14.04M 183M 14.21M 13.9M 581M